I know previously i've speculated that Roches target is likely to be Alzheimers/Parkinsons disease areas as this is where they currently have programs active but i just heard a interview on ABC radio in Adelaide with Professor Bob Vink the Chair of the NeuroSurgical Research Foundation and Head of the School of Medical Sciences at the University of Adelaide on the opening today of a new Brain Tumour Research Lab in Adelaide this morning with funding from Santos & the SA Police.
A very interesting conversation & opened my eyes alot wider to the unmet market than i had previously thought despite persoanlly knowing someone that passed away suddenly many years ago as a teenager from brain cancer.
I'lll just put a few figures & facts out there that he put forward as it actually was a big wake up & i wouldn;t at all be suprised if this is where roche is know heading.
*** is one of Australia's most aggressive and least understood cancers, which kills one Australian every six hours.
*** More than 1400 people die of brain cancer each year in Australia and it accounts for more than one third of cancer deaths in children aged under 10
*** Deaths from brain cancer now sigfnificantly out-number any other cancers in Australia mainly because methods of treatment for other cancers has significantly improved over time while Brain Cancers have been gridlocked. A large part of this is inability to access the brain directly eg- breach the blood-brain barrier
*** Brain Cancers often result from other cancers spreading to the brain over time as they progress.
Anyway heres a link to the official release -
New lab will help identify causes of brain cancer
- Forums
- ASX - By Stock
- brain cancer & the blood brain-barrier
I know previously i've speculated that Roches target is likely...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PYC (ASX) to my watchlist
(20min delay)
|
|||||
Last
19.0¢ |
Change
-0.005(2.56%) |
Mkt cap ! $874.8M |
Open | High | Low | Value | Volume |
20.0¢ | 20.0¢ | 18.5¢ | $211.4K | 1.108M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 90135 | 19.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
19.5¢ | 353 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 68702 | 0.190 |
12 | 229822 | 0.185 |
17 | 402312 | 0.180 |
6 | 343750 | 0.175 |
11 | 495063 | 0.170 |
Price($) | Vol. | No. |
---|---|---|
0.195 | 67282 | 5 |
0.200 | 749938 | 10 |
0.205 | 743795 | 9 |
0.210 | 1008672 | 8 |
0.215 | 878610 | 4 |
Last trade - 15.37pm 12/11/2024 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online